GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells

GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells

We defined the lethal interaction between the novel therapeutic GZ17-6.02 and the standard of care combination of the MEK1/2 inhibitor trametinib and the B-RAF inhibitor dabrafenib in PDX isolates of cutaneous melanoma expressing a mutant B-RAF V600E protein. GZ17-6.02 interacted with trametinib/dab...

Full description

Bibliographic Details
Main Authors: Laurence Booth, Cameron West, Daniel Von Hoff, John M. Kirkwood, Paul Dent
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Oncology
Subjects:
B-Raf mutation V600E
GZ17-6.02
autophagy
er stress
HDAC
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.656453/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.656453/full

Similar Items